Abstract
Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 167-170 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 6 |
| Issue number | 2 |
| State | Published - 1983 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study. / Ettinger, David S; Day, R.; Ferraro, J. A.; Ruckdeschel, J. C.; Woll, J. E.; Creech, R. H.; Vogl, S. E.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 6, No. 2, 1983, p. 167-170.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study
AU - Ettinger, David S
AU - Day, R.
AU - Ferraro, J. A.
AU - Ruckdeschel, J. C.
AU - Woll, J. E.
AU - Creech, R. H.
AU - Vogl, S. E.
PY - 1983
Y1 - 1983
N2 - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.
AB - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0020535590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020535590&partnerID=8YFLogxK
M3 - Article
C2 - 6299093
AN - SCOPUS:0020535590
VL - 6
SP - 167
EP - 170
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 2
ER -